According to license agreement terms, T-Cure will receive an unspecified upfront payment from Immunotech, along with future development milestone payments and tiered royalties on net sales of the treatment.
T-Cure’s renal cancer immunotherapy product, referred to as 800TCR, is in Phase 1 clinical trials.
“With its advanced research, manufacturing, clinical operations and marketing, Immunotech represents an ideal partner to help us advance the 800TCR in China,” Dr. Gang Teng, chief executive of T-Cure, said in a statement.
“Our company made a strong debut last year as the first pre-revenue cellular immunotherapy firm to trade on the Hong Kong Stock Exchange,” added Dr. Wang Yu, chief executive of Immunotech. “We see the addition of 800TCR as a natural expansion of our cell therapy product pipeline.”